390 related articles for article (PubMed ID: 33798262)
1. Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin.
Brouwer NJ; Konstantinou EK; Gragoudas ES; Marinkovic M; Luyten GPM; Kim IK; Jager MJ; Vavvas DG
Invest Ophthalmol Vis Sci; 2021 Apr; 62(4):3. PubMed ID: 33798262
[TBL] [Abstract][Full Text] [Related]
2. Combination of Molecule-Targeted Therapy and Photodynamic Therapy Using Nanoformulated Verteporfin for Effective Uveal Melanoma Treatment.
Song M; Zhu L; Zhang L; Ge X; Cao J; Teng Y; Tian R
Mol Pharm; 2024 May; 21(5):2340-2350. PubMed ID: 38546166
[TBL] [Abstract][Full Text] [Related]
3. YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression.
Li H; Li Q; Dang K; Ma S; Cotton JL; Yang S; Zhu LJ; Deng AC; Ip YT; Johnson RL; Wu X; Punzo C; Mao J
Cell Rep; 2019 Dec; 29(10):3200-3211.e4. PubMed ID: 31801083
[TBL] [Abstract][Full Text] [Related]
4. YAP Activity is Not Associated with Survival of Uveal Melanoma Patients and Cell Lines.
Kim YJ; Lee SC; Kim SE; Kim SH; Kim SK; Lee CS
Sci Rep; 2020 Apr; 10(1):6209. PubMed ID: 32277165
[TBL] [Abstract][Full Text] [Related]
5. Comparing the Hem- and Lymphangiogenic Profile of Conjunctival and Uveal Melanoma Cell Lines.
Refaian N; Schlereth SL; Koch KR; Notara M; Hos D; Mescher M; Iden S; Bosch JJ; Jager MJ; Cursiefen C; Heindl LM
Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5691-7. PubMed ID: 26313304
[TBL] [Abstract][Full Text] [Related]
6. Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma.
Mergener S; Siveke JT; Peña-Llopis S
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201614
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
[TBL] [Abstract][Full Text] [Related]
8. Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling.
Liu H; Lei C; Long K; Yang X; Zhu Z; Zhang L; Liu J
Oncol Rep; 2015 Jul; 34(1):295-301. PubMed ID: 25955651
[TBL] [Abstract][Full Text] [Related]
9. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.
Yu FX; Luo J; Mo JS; Liu G; Kim YC; Meng Z; Zhao L; Peyman G; Ouyang H; Jiang W; Zhao J; Chen X; Zhang L; Wang CY; Bastian BC; Zhang K; Guan KL
Cancer Cell; 2014 Jun; 25(6):822-30. PubMed ID: 24882516
[TBL] [Abstract][Full Text] [Related]
10. TAZ and YAP are frequently activated oncoproteins in sarcomas.
Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
[TBL] [Abstract][Full Text] [Related]
11. High expression of TAZ/YAP promotes the progression of malignant melanoma and affects the postoperative survival of patients.
Feng Q; Guo P; Kang S; Zhao F
Pharmazie; 2018 Nov; 73(11):662-665. PubMed ID: 30396386
[No Abstract] [Full Text] [Related]
12. Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist.
Martorano LM; Winkelmann RR; Cebulla CM; Abdel-Rahman MH; Campbell SM
Int J Dermatol; 2014 Jun; 53(6):657-63. PubMed ID: 24697775
[TBL] [Abstract][Full Text] [Related]
13. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma.
Ewens KG; Kanetsky PA; Richards-Yutz J; Purrazzella J; Shields CL; Ganguly T; Ganguly A
Invest Ophthalmol Vis Sci; 2014 Jun; 55(8):5160-7. PubMed ID: 24970262
[TBL] [Abstract][Full Text] [Related]
14. BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors.
Han A; Purwin TJ; Bechtel N; Liao C; Chua V; Seifert E; Sato T; Schug ZT; Speicher DW; Harbour JW; Aplin AE
Oncogene; 2021 Jan; 40(3):618-632. PubMed ID: 33208912
[TBL] [Abstract][Full Text] [Related]
15. The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability.
Li Y; He J; Qiu C; Shang Q; Qian G; Fan X; Ge S; Jia R
J Cell Biochem; 2019 Apr; 120(4):5766-5776. PubMed ID: 30320917
[TBL] [Abstract][Full Text] [Related]
16. Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes.
Decatur CL; Ong E; Garg N; Anbunathan H; Bowcock AM; Field MG; Harbour JW
JAMA Ophthalmol; 2016 Jul; 134(7):728-33. PubMed ID: 27123562
[TBL] [Abstract][Full Text] [Related]
17. BAP1 germline mutation in two first grade family members with uveal melanoma.
Maerker DA; Zeschnigk M; Nelles J; Lohmann DR; Worm K; Bosserhoff AK; Krupar R; Jägle H
Br J Ophthalmol; 2014 Feb; 98(2):224-7. PubMed ID: 24187051
[TBL] [Abstract][Full Text] [Related]
18. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma.
Patrone S; Maric I; Rutigliani M; Lanza F; Puntoni M; Banelli B; Rancati S; Angelini G; Amaro A; Ligorio P; Defferrari C; Castagnetta M; Bandelloni R; Mosci C; DeCensi A; Romani M; Pfeffer U; Viaggi S; Coviello DA
Genes Chromosomes Cancer; 2018 Aug; 57(8):387-400. PubMed ID: 29689622
[TBL] [Abstract][Full Text] [Related]
20. HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma.
Sriramareddy SN; Faião-Flores F; Emmons MF; Saha B; Chellappan S; Wyatt C; Smalley I; Licht JD; Durante MA; Harbour JW; Smalley KSM
Cancer Gene Ther; 2022 Dec; 29(12):1840-1846. PubMed ID: 35332245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
